Enterprise (EPD) Q4 Earnings Meet, Revenues Beat Estimates

In this article:

Earnings In Line: Headquartered in Houston, TX, Enterprise Products Partners L.P. EPD reported adjusted fourth-quarter earnings of 54 cents per unit, same as the Zacks Consensus Estimate.  

Estimate Revision Trend & Surprise History: Investors should note that the Zacks Consensus Estimate of earnings for the quarter has been unchanged in the past seven days.

Enterprise Products has an impressive earnings surprise history. The partnership managed to beat the Zacks Consensus Estimate in three of the last four quarters, the average positive earnings surprise being roughly 9.85%.

Enterprise Products Partners L.P. Price and EPS Surprise

Enterprise Products Partners L.P. Price and EPS Surprise
Enterprise Products Partners L.P. Price and EPS Surprise

Enterprise Products Partners L.P. price-eps-surprise | Enterprise Products Partners L.P. Quote

Revenues Beat: Revenues of $8,005.3 million surpassed the Zacks Consensus Estimate of $7,973 million.

Key Stats: Adjusted distributable cash flow was recorded at $1.6 billion, up 12% year over year and provided coverage of 1.7x. The partnership has retained $654 million of distributable cash flow.

Notably, NGL, crude oil, refined products & petrochemical pipeline volumes were recorded at 6.9 million barrels per day level in the fourth quarter of 2019.

Zacks Rank: Currently, Enterprise Products has a Zacks Rank #3 (Hold) but that could change following its third-quarter 2019 report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Check back later for our full write up on this Enterprise Products earnings report later!

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Enterprise Products Partners L.P. (EPD) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement